Glenmark Life Sciences Limited (IN:ALIVUS)
:ALIVUS
Want to see IN:ALIVUS full AI Analyst Report?
Top Page
Glenmark Life Sciences Limited
(ALIVUS)
Select Model
Select Model
Rating:71Outperform
Price Target:
₹1,146.00
▲(24.46% Upside)
Action:N/ADate:02/19/26
The score is driven primarily by strong financial quality—especially the low-leverage balance sheet and solid margins—offset by only modest recent growth and less consistent cash-to-earnings conversion. Technical signals are neutral and valuation is reasonable but not particularly cheap, with a low dividend yield.
Positive Factors
Very low leverage and strong equity base
A very low debt-to-equity ratio and an expanded equity base provide durable financial flexibility: the company can invest in capacity, absorb regulatory or demand shocks, and pursue M&A or buybacks without risking solvency. Healthy ROE (~20%) shows efficient capital use over time.
Negative Factors
Modest recent revenue growth
Slower top-line expansion reduces the company’s ability to scale fixed-cost advantages and limits long-term earnings leverage. In a capital-intensive API business, modest revenue growth constrains margin expansion, limits market share gains, and increases reliance on margin maintenance to drive returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage and strong equity base
A very low debt-to-equity ratio and an expanded equity base provide durable financial flexibility: the company can invest in capacity, absorb regulatory or demand shocks, and pursue M&A or buybacks without risking solvency. Healthy ROE (~20%) shows efficient capital use over time.
Read all positive factors
Glenmark Life Sciences Limited (ALIVUS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹127.34B
Dividend Yield0.56%
Average Volume (3M)7.13K
Price to Earnings (P/E)18.7
Beta (1Y)0.76
Revenue Growth10.48%
EPS Growth22.99%
CountryIN
Employees2,203
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)22.17
Shares Outstanding122,736,350
10 Day Avg. Volume3,315
30 Day Avg. Volume7,125
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)4.50
Price to Sales (P/S)5.34
P/FCF Ratio51.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)52.7
Revenue Forecast (FY)₹28.31B
Glenmark Life Sciences Limited Business Overview & Revenue Model
Company Description
Alivus Life Sciences Limited develops, manufactures, and markets active pharmaceutical ingredients in India, Japan, Europe, North and Latin America, and internationally. It offers various APIs, such as olmesartan, telmisartan, solifenacin, sitagli...
How the Company Makes Money
The company makes money primarily by selling active pharmaceutical ingredients (APIs) and intermediates to pharmaceutical manufacturers. Its revenue is generated through (1) commercial supply of APIs manufactured at its facilities and sold to cust...
Glenmark Life Sciences Limited Financial Statement Overview
Summary
Income Statement
82
Very Positive
Balance Sheet
90
Very Positive
Cash Flow
74
Positive
| Breakdown | TTM | Mar 2024 | Mar 2022 | Mar 2021 | Mar 2019 | Mar 2018 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.90B | 23.72B | 21.23B | 18.85B | 14.05B | 2.48M |
| Gross Profit | 5.56B | 7.64B | 10.80B | 9.80B | 7.79B | 110.00K |
| EBITDA | 4.02B | 7.17B | 6.31B | 5.92B | 2.48B | 10.00K |
| Net Income | 2.72B | 4.86B | 4.19B | 3.52B | 2.93B | -4.34M |
Balance Sheet | ||||||
| Total Assets | 36.38B | 34.11B | 24.71B | 19.97B | 14.75B | 850.00K |
| Cash, Cash Equivalents and Short-Term Investments | 6.53B | 5.49B | 5.17B | 1.40B | 78.48M | 70.00K |
| Total Debt | 1.13B | 566.06M | 28.84M | 9.33B | 210.00K | 14.50M |
| Total Liabilities | 6.23B | 5.94B | 4.17B | 12.44B | 13.87B | 14.83M |
| Stockholders Equity | 30.15B | 28.17B | 20.54B | 7.53B | 881.25M | -13.98M |
Cash Flow | ||||||
| Free Cash Flow | 2.39B | 2.45B | 4.65B | 3.20B | 10.27M | -4.81M |
| Operating Cash Flow | 4.33B | 4.11B | 5.98B | 3.88B | 103.52M | -4.81M |
| Investing Cash Flow | -7.95B | -6.36B | -1.22B | -687.34M | -89.14M | 0.00 |
| Financing Cash Flow | -649.40M | -61.14M | -787.96M | -2.14B | 5.35M | 4.86M |
Glenmark Life Sciences Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ₹127.34B | 18.72 | ― | 0.56% | 10.48% | 22.99% | |
71 Outperform | ₹83.68B | 18.03 | ― | 0.44% | 13.29% | -2.17% | |
71 Outperform | ₹78.49B | 18.01 | ― | 4.73% | -12.98% | -21.81% | |
69 Neutral | ₹130.03B | 21.31 | ― | 0.31% | 10.66% | 19.05% | |
66 Neutral | ₹173.27B | 18.85 | ― | 0.24% | 19.73% | 18.17% | |
54 Neutral | ₹79.58B | 35.22 | ― | 0.16% | 14.80% | 63.75% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:ALIVUS
Glenmark Life Sciences Limited
1,037.50
-43.74
-4.05%
IN:CAPLIPOINT
Caplin Point Laboratories Limited
1,710.60
-180.58
-9.55%
IN:GRANULES
Granules India Limited
699.25
238.41
51.73%
IN:MARKSANS
Marksans Pharma Limited
184.65
-36.92
-16.66%
IN:SANOFI
Sanofi India Limited
3,407.95
-2,281.96
-40.11%
IN:SHILPAMED
Shilpa Medicare Limited
406.90
73.43
22.02%
Glenmark Life Sciences Limited Corporate Events
Alivus Life Sciences Schedules Analyst and Institutional Investor Meetings
Mar 6, 2026
Alivus Life Sciences Limited has announced a schedule of meetings with analysts and institutional investors as part of its regulatory disclosure obligations. The company will hold one-on-one sessions with ICICI Direct via a virtual meeting on Marc...
Alivus says Dahej fire impact limited, production to restart in March
Feb 25, 2026
Alivus Life Sciences has clarified the operational impact of a February 14 fire at its Dahej manufacturing facility in Gujarat, confirming that the incident was confined to one of seven production blocks and affected only a portion of its intermed...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.